Background Tongxinluo capsule is a new drug for cardio- cerebral vascular diseases on the national essential drug list of China, and the second-class award of National Science and Technology Development of China, 2001.
Objective This review aims to assess the effect (harms and benefits) of Tongxinluo capsule for unstable angina.
Search strategy electronic searchs The Cochrane Heart Review Group specialised trials register,The Cochrane Controlled Trials Register, published in the latest issue of the Cochrane Library, MEDLINE, EMBASE, CBM, Chinese Cochrane Centre Controlled Trials Register, Current Controlled Trials (www. controlled-trials. com), The National Research Register
Handsearchs We will search 83 journals of Chinese traditional medicine.
Inclusion riteria We will include randomised controlled trials of Tonxinluo capsule versus placebo or other current phamarcotherapy or other Chinese medicinal herbs in the participants with unstable angina pectoris. Studies will report mortality (sudden death from acute myocardial infarction), severity of angina pectoris, frequency of acute attack angina, ECG improvement, rate of dosage reducing or taking frequency of nitroglycerine and symptom improvement, etc.
Data analysis Data will be included in a meta-analysis if they are available, of sufficient quality and sufficiently similar.
Citation： WU Taixiang,Harrison Roger,LIU Guanjian,HAO Baoqin,ZHOU Likun,WEI Jiafu,WANG Qin,NI Juan,DUAN Xin,QIAO Jieqi,CHEN Xiaoyan,ZHENG Jie. A Cochrane systematic review protocol of Tongxinluo capsule for unstable angina pectoris. Chinese Journal of Evidence-Based Medicine, 2003, 03(1): 26-34. doi: Copy
Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved